Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses
Nissinen, T., Hentilä, J., Penna, F., Lampinen, A., Lautaoja, J., Fachada, V., Holopainen, T., Ritvos, O., Kivelä, R., & Hulmi, J. (2018). Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. Journal of Cachexia, Sarcopenia and Muscle, 9(3), 514-529. https://doi.org/10.1002/jcsm.12310
Julkaistu sarjassa
Journal of Cachexia, Sarcopenia and MuscleTekijät
Päivämäärä
2018Tekijänoikeudet
© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders
Background
Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered.
Methods
The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non‐muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B‐Fc). Treatment with sACVR2B‐Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non‐muscle tissues in cancer cachexia were investigated in order to understand the possible mechanisms of improved survival mediated by ACVR2 ligand blocking.
Results
Blocking of ACVR2 ligands improved survival in tumour‐bearing mice only when the mice were treated both before and after the tumour formation. This occurred without effects on tumour growth, production of pro‐inflammatory cytokines or the level of physical activity. ACVR2 ligand blocking was associated with increased muscle (limb and diaphragm) mass and attenuation of both hepatic protein synthesis and splenomegaly. Especially, the effects on the liver and the spleen were observed independent of the treatment protocol. The prevention of splenomegaly by sACVR2B‐Fc was not explained by decreased markers of myeloid‐derived suppressor cells. Decreased tibialis anterior, diaphragm, and heart protein synthesis were observed in cachectic mice. This was associated with decreased mechanistic target of rapamycin (mTOR) colocalization with late‐endosomes/lysosomes, which correlated with cachexia and reduced muscle protein synthesis.
Conclusions
The prolonged survival with continued ACVR2 ligand blocking could potentially be attributed in part to the maintenance of limb and respiratory muscle mass, but many observed non‐muscle effects suggest that the effect may be more complex than previously thought. Our novel finding showing decreased mTOR localization in skeletal muscle with lysosomes/late‐endosomes in cancer opens up new research questions and possible treatment options for cachexia.
...
Julkaisija
WileyISSN Hae Julkaisufoorumista
2190-5991Asiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/28041016
Metadata
Näytä kaikki kuvailutiedotKokoelmat
- Liikuntatieteiden tiedekunta [3139]
Rahoittaja(t)
Suomen AkatemiaRahoitusohjelmat(t)
Akatemiatutkija, SALisätietoja rahoituksesta
This work was supported by the Academy of Finland [grant No. 275922 (JJH) and 297245 (RK)], Cancer Society of Finland (JJH), and Jenny and Antti Wihuri Foundation (TAN, RK). We also thank Dr Philippe Pierre for kindly providing the anti‐puromycin antibody. We acknowledge Arja Pasternack, Mika Silvennoinen, Maarit Lehti, Sanna Lensu, Sira Karvinen, Mervi Matero, Jouni Härkönen, Aila Ollikainen, Risto Puurtinen, Kaisa‐Leena Tulla, Eliisa Kiukkanen, Minna Savela, and Jouni Tukiainen for their valuable help and technical assistance. ...Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting
Nissinen, Tuuli A.; Hentilä, Jaakko; Fachada, Vasco; Lautaoja, Juulia H.; Pasternack, Arja; Ritvos, Olli; Kivelä, Riikka; Hulmi, Juha J. (John Wiley & Sons, 2021)Blocking of myostatin and activins effectively counteracts muscle atrophy. However, the potential interaction with physical inactivity and fasting in the regulation of muscle protein synthesis is poorly understood. We used ... -
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
Hentilä, Jaakko; Nissinen, Tuuli; Korkmaz, Ayhan; Lensu, Sanna; Silvennoinen, Mika; Pasternack, Arja; Ritvos, Olli; Atalay, Mustafa; Hulmi, Juha (Frontiers Research Foundation, 2019)Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein synthesis/degradation. These changes in cellular and protein metabolism may alter protein ... -
Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle
Hulmi, Juha; Nissinen, Tuuli; Räsänen, Markus; Degerman, Joni; Lautaoja, Juulia; Hemanthakumar, Karthik Amudhala; Backman, Janne T.; Ritvos, Olli; Silvennoinen, Mika; Kivelä, Riikka (Wiley, 2018)Background Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, and decreased quality of life. Doxorubicin (DOX) is an effective cytostatic agent, which ... -
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota : A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
Pekkala, Satu; Keskitalo, Anniina; Kettunen, Emilia; Lensu, Sanna; Nykänen, Noora; Kuopio, Teijo; Ritvos, Olli; Hentilä, Jaakko; Nissinen, Tuuli A.; Hulmi, Juha J. (MDPI AG, 2019)Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. We characterized the CRC-associated microbiota and investigated whether cachexia affects the microbiota composition. ... -
Activin-A, myostatin and interleukin-6 in cancer associated cachexia
Härkönen, Jouni (2017)Cachexia is a muscle wasting condition associated with multiple different chronic illnesses, such as cancer, diabetes and AIDS. In cancer, approximately 80% of patients with advanced disease have symptoms of muscle wasting, ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.